Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Announcing the $256 million deal, the New York-based biotech firm vowed to comply with 23andMe’s privacy policy, which was a ...

Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy ...

Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

By Michael Levenson 23andMe, the genetic testing company that was once valued at $6 billion but filed for bankruptcy in March, will be bought by Regeneron Pharmaceuticals, a biotechnology company ...

A webcast of the presentation can be found under the IR Events tab of the Tonix website at www.tonixpharma.com.

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving ...

Story March 6 - Atea Pharmaceuticals: After giving up on its COVID ambitions last year, Atea revealed in its annual financial results that during the first quarter of 2025, the biotech has slashed ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's ...

Commerce officials approved an incentives package worth up to $13.1 million for the company, which plans to build a $700 ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...